Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02300870 · ClinicalTrials.gov registry record
Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection
A clinical trial, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- 10
- Enrollment target
NCT02300870: Clinical Trial study, sponsored by Brigham and Women's Hospital.
NCT02300870 is a clinical trial that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02300870 was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans. The secondary objective is to demonstrate the efficacy of this technique in generating data which allow for the assessment of short and long term outcomes.
Primary Outcome
Myocardial blood flow (dB/s)
Interventions
- DRUG Optison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-12 |
Why NCT02300870 stopped before completion
NCT02300870 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Optison is the first listed.
NCT02300870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02300870 about?
NCT02300870 is a clinical study titled "Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection". The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans. The secondary objective is to demonstrate the efficacy of this technique in generating data which allow for the assessment of short and long term out...
What is the current status of trial NCT02300870?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2015-01. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02300870?
The interventions under investigation include: Optison (DRUG).
Who is sponsoring clinical trial NCT02300870?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia